Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137

Shi-Yan Li, Yizhen Liu Cancer Research Institute, Scott and White Healthcare, Temple, TX, USA Abstract: Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li SY, Liu Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/1cbbf2420ab54533883a9b795cdf6c50
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1cbbf2420ab54533883a9b795cdf6c50
record_format	dspace
spelling	oai:doaj.org-article:1cbbf2420ab54533883a9b795cdf6c502021-12-02T07:39:20ZImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD1371179-1438https://doaj.org/article/1cbbf2420ab54533883a9b795cdf6c502013-09-01T00:00:00Zhttp://www.dovepress.com/immunotherapy-of-melanoma-with-the-immune-costimulatory-monoclonal-ant-a14227https://doaj.org/toc/1179-1438Shi-Yan Li, Yizhen Liu Cancer Research Institute, Scott and White Healthcare, Temple, TX, USA Abstract: Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical responses and confirmed that the immune system can significantly inhibit tumor progression. Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. CD137 (also known as 4-1BB) a member of the tumor necrosis factor (TNF) receptor superfamily, is an activation-induced T cell costimulator molecule. Growing evidence indicates that anti-CD137 monoclonal antibodies possess strong antitumor properties, the result of their powerful capability to activate CD8+ T cells, to produce interferon (IFN)-γ, and to induce cytolytic markers. Combination therapy of anti-CD137 with other anticancer agents, such as radiation, has robust tumor-regressing abilities against nonimmunogenic or poorly immunogenic tumors. Of importance, targeting CD137 eliminates established tumors, and the fact that anti-CD137 therapy acts in concert with other anticancer agents and/or radiation therapy to eradicate nonimmunogenic and weakly immunogenic tumors is an additional benefit. Currently, BMS-663513, a humanized anti-CD137 antibody, is in clinical trials in patients with solid tumors, including melanoma, renal carcinoma, ovarian cancer, and B-cell malignancies. In this review, we discuss the basis of the therapeutic potential of targeting CD137 in cancer treatment, focusing in particular, on BMS-663513 as an immune costimulatory monoclonal antibody for melanoma immunotherapy. Keywords: anti-CD137 monoclonal antibodies, immune costimulator molecule, BMS-663513Li SYLiu YDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Supplement 1, Pp 47-53 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Li SY Liu Y Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
description	Shi-Yan Li, Yizhen Liu Cancer Research Institute, Scott and White Healthcare, Temple, TX, USA Abstract: Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical responses and confirmed that the immune system can significantly inhibit tumor progression. Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. CD137 (also known as 4-1BB) a member of the tumor necrosis factor (TNF) receptor superfamily, is an activation-induced T cell costimulator molecule. Growing evidence indicates that anti-CD137 monoclonal antibodies possess strong antitumor properties, the result of their powerful capability to activate CD8+ T cells, to produce interferon (IFN)-γ, and to induce cytolytic markers. Combination therapy of anti-CD137 with other anticancer agents, such as radiation, has robust tumor-regressing abilities against nonimmunogenic or poorly immunogenic tumors. Of importance, targeting CD137 eliminates established tumors, and the fact that anti-CD137 therapy acts in concert with other anticancer agents and/or radiation therapy to eradicate nonimmunogenic and weakly immunogenic tumors is an additional benefit. Currently, BMS-663513, a humanized anti-CD137 antibody, is in clinical trials in patients with solid tumors, including melanoma, renal carcinoma, ovarian cancer, and B-cell malignancies. In this review, we discuss the basis of the therapeutic potential of targeting CD137 in cancer treatment, focusing in particular, on BMS-663513 as an immune costimulatory monoclonal antibody for melanoma immunotherapy. Keywords: anti-CD137 monoclonal antibodies, immune costimulator molecule, BMS-663513
format	article
author	Li SY Liu Y
author_facet	Li SY Liu Y
author_sort	Li SY
title	Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
title_short	Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
title_full	Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
title_fullStr	Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
title_full_unstemmed	Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
title_sort	immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting cd137
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/1cbbf2420ab54533883a9b795cdf6c50
work_keys_str_mv	AT lisy immunotherapyofmelanomawiththeimmunecostimulatorymonoclonalantibodiestargetingcd137 AT liuy immunotherapyofmelanomawiththeimmunecostimulatorymonoclonalantibodiestargetingcd137
_version_	1718399266345451520

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137

Ejemplares similares